Biotechnology News and Research

RSS

WSJ: Biotech generics battle heats up

A battle is heating up over the meaning of a single word in the health overhaul that could mean billions of dollars to the makers of biotechnology drugs (Mundy, 1/26).

27 Jan 2011

Anapharm Europe, PharmaNet officially terminate joint venture

PharmaNet Development Group, and Anapharm Europe, S.L., both leading providers of drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries, announced that their joint venture for the collaborative provision of bioanalytical services officially ended December 22, 2010.

27 Jan 2011

Teva, APP enter agreement for launch of generic Gemzar

Teva Pharmaceutical Industries Ltd. and APP Pharmaceuticals, Inc. announced today the commercial launch of Gemcitabine HCI for Injection in 200 mg and 1 g single dose vials, the generic version of Gemzar®, in the United States, pursuant to a commercialization, manufacture and supply agreement signed by the two companies.

26 Jan 2011

First Edition: January 26, 2011

Reporting for KHN, in collaboration with Politico, Bara Vaida writes: "Lobbyists for doctors, hospitals and drug companies are urging lawmakers to derail a planned government panel that health industry officials fear will sharply curb Medicare spending -- a critical revenue source for them".

26 Jan 2011

Anadys begins dosing in ANA598 Phase IIb study for hepatitis C

Anadys Pharmaceuticals, announced today that dosing has begun in the Phase IIb study of ANA598 in combination with pegylated interferon and ribavirin in hepatitis C patients.

26 Jan 2011

Microvisk secures £6 million to launch world's first diagnostic SmartStrip

Microvisk Technologies, the developer of a handheld system to monitor the blood clotting status of patients taking the drug Warfarin, has raised £6 million through a rights issue to existing investors in an oversubscribed round. This is the third successful funding round for Microvisk, which has secured £10.5m in the past 12 months - the largest amount raised by a UK life science company**.

26 Jan 2011

Spine surgeon successfully treated with RNL Bio's stem cell therapy for Autoimmune Arthritis

RNL BIO CO., LTD, a leading biopharmaceutical company specialized in adult stem cell therapeutics, announced on January 21, 2011 another successful patient report utilizing stem cell therapy on a leading US orthopedic spine surgeon who suffered from Autoimmune Arthritis.

26 Jan 2011

Nordion and Sterigenics sign five year contract for Cobalt-60 supply

Nordion Inc., a leading provider of products and services to the global health science market, today announced it has signed a five-year contract with Sterigenics International, a global leader in contract sterilization and ionization services, for the supply of Cobalt-60. Under the terms of the agreement, this contract extends until October 31, 2015.

25 Jan 2011

Taiwanese research team develops large-scale proactive cancer treatment system first-generation prototype

A Taiwanese research team, led by Prof. Ming-Shing Young of Department of Electrical Engineering at National Cheng Kung University (NCKU), has successfully developed a large-scale proactive cancer treatment system first-generation prototype which includes Frequency-Adjustable High Frequency Induction Heating Machine (HFIHM) and 3D Magnetically Guiding Endoscope System (3DMGES).

25 Jan 2011

RRD enters partnership with NIH Therapeutics for Rare and Neglected Diseases program

RRD International, a strategy-driven biotech and pharmaceutical product development company, announced today that it has entered into a partnership with the National Institutes of Health (NIH) Therapeutics for Rare and Neglected Diseases (TRND) program as a regulatory support and development partner.

25 Jan 2011

FedEx launches Deep Frozen Shipping Solution for temperature-sensitive healthcare products

FedEx Corp. today announced the launch of FedEx Deep Frozen Shipping Solution, which offers an innovative end-to-end service for the shipping of temperature-sensitive healthcare products around the world.

24 Jan 2011

Myriant closes $60M strategic equity investment from PTT Chemical

Myriant Technologies, Inc., a privately-held, biotech developer and manufacturer of renewable bio-based chemicals, announced today the closing of a $60 million strategic equity investment from PTT Chemical Group, Thailand's largest petrochemical producer.

24 Jan 2011

Furiex's MuDelta for diarrhea-predominant irritable bowel syndrome receives FDA Fast Track designation

Furiex Pharmaceuticals, Inc. today announced that its novel diarrhea-predominant irritable bowel syndrome treatment called MuDelta, now in Phase II clinical trials, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).

24 Jan 2011

ArQule's ARQ 197 Phase 1 clinical trial results in colorectal cancer presented at ASCO 2011

ArQule, Inc. today announced the presentation of Phase 1 results of a clinical trial among patients with metastatic colorectal cancer (CRC) treated with ARQ 197, a selective small molecule inhibitor of the c-MET receptor tyrosine kinase, in combination with irinotecan and cetuximab. ARQ 197 is under development by Daiichi Sankyo Co., Ltd. and ArQule.

24 Jan 2011

Threshold reports positive results from TH-302 Phase 1/2 clinical trial in pancreatic cancer

Threshold Pharmaceuticals, Inc. today announced updated Phase 1/2 clinical trial results related to the Company's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the ASCO Gastro Intestinal Cancers Symposium that took place in San Francisco from January 20-22, 2011.

24 Jan 2011

Senesco files SNS01-T IND for treatment of multiple myeloma

Senesco Technologies, Inc. today announced that the Company has filed an Investigational New Drug application with the U.S. Food and Drug Administration for Senesco's lead drug candidate SNS01-T for treatment of multiple myeloma.

24 Jan 2011

Agenus enters research agreement with Memorial Sloan-Kettering Cancer Center

Agenus Inc. today announced it has entered into a research agreement with Memorial Sloan-Kettering Cancer Center (MSKCC) using Agenus' proprietary cancer vaccine technology.

24 Jan 2011

Spectrum submits Post Approval Supplement for removal of bioscan requirement for Indium-111 ZEVALIN

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that on Thursday, January 20, 2011, it submitted a Post Approval Supplement containing data supporting the removal of the Indium-111 ZEVALIN® pre-treatment imaging evaluation, more commonly referred to as the "bioscan" requirement.

24 Jan 2011

Northwest Biotherapeutics resumes enrollment in DCVax Phase II clinical trial for GBM brain cancer

Northwest Biotherapeutics announced today that the Company is resuming enrollment of additional new patients into its ongoing 240-patient, double blind, randomized, placebo controlled Phase II clinical trial of DCVax for Glioblastoma multiforme brain cancer.

24 Jan 2011

FDA approves Clinical Data's Viibryd for major depressive disorder

Clinical Data, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved vilazodone HCl tablets, to be marketed under the brand name Viibryd™, for the treatment of adults with major depressive disorder (MDD).

24 Jan 2011

Biotechnology News and Research

WSJ: Biotech generics battle heats up

Anapharm Europe, PharmaNet officially terminate joint venture

Teva, APP enter agreement for launch of generic Gemzar

First Edition: January 26, 2011

Anadys begins dosing in ANA598 Phase IIb study for hepatitis C

Microvisk secures £6 million to launch world's first diagnostic SmartStrip

Spine surgeon successfully treated with RNL Bio's stem cell therapy for Autoimmune Arthritis

Nordion and Sterigenics sign five year contract for Cobalt-60 supply

Taiwanese research team develops large-scale proactive cancer treatment system first-generation prototype

RRD enters partnership with NIH Therapeutics for Rare and Neglected Diseases program

FedEx launches Deep Frozen Shipping Solution for temperature-sensitive healthcare products

Myriant closes $60M strategic equity investment from PTT Chemical

Furiex's MuDelta for diarrhea-predominant irritable bowel syndrome receives FDA Fast Track designation

ArQule's ARQ 197 Phase 1 clinical trial results in colorectal cancer presented at ASCO 2011

Threshold reports positive results from TH-302 Phase 1/2 clinical trial in pancreatic cancer

Senesco files SNS01-T IND for treatment of multiple myeloma

Agenus enters research agreement with Memorial Sloan-Kettering Cancer Center

Spectrum submits Post Approval Supplement for removal of bioscan requirement for Indium-111 ZEVALIN

Northwest Biotherapeutics resumes enrollment in DCVax Phase II clinical trial for GBM brain cancer

FDA approves Clinical Data's Viibryd for major depressive disorder

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News